Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bruce A. Hay is active.

Publication


Featured researches published by Bruce A. Hay.


Journal of Pharmacology and Experimental Therapeutics | 2008

Pharmacologic Inhibition of Site 1 Protease Activity Inhibits Sterol Regulatory Element-Binding Protein Processing and Reduces Lipogenic Enzyme Gene Expression and Lipid Synthesis in Cultured Cells and Experimental Animals

Julie Hawkins; Michael D. Robbins; Laurie C. Warren; Donghui Xia; Stephen F. Petras; James J. Valentine; Alison H. Varghese; Ing-Kae Wang; Timothy A. Subashi; Lorraine D. Shelly; Bruce A. Hay; Katherine T. Landschulz; Kieran F. Geoghegan; H. James Harwood

Sterol regulatory element-binding proteins (SREBPs) are major transcriptional regulators of cholesterol, fatty acid, and glucose metabolism. Genetic disruption of SREBP activity reduces plasma and liver levels of cholesterol and triglycerides and insulin-stimulated lipogenesis, suggesting that SREBP is a viable target for pharmacological intervention. The proprotein convertase SREBP site 1 protease (S1P) is an important posttranscriptional regulator of SREBP activation. This report demonstrates that 10 μM PF-429242 (Bioorg Med Chem Lett 17:4411–4414, 2007), a recently described reversible, competitive aminopyrrolidineamide inhibitor of S1P, inhibits endogenous SREBP processing in Chinese hamster ovary cells. The same compound also down-regulates the signal from an SRE-luciferase reporter gene in human embryonic kidney 293 cells and the expression of endogenous SREBP target genes in cultured HepG2 cells. In HepG2 cells, PF-429242 inhibited cholesterol synthesis, with an IC50 of 0.5 μM. In mice treated with PF-429242 for 24 h, the expression of hepatic SREBP target genes was suppressed, and the hepatic rates of cholesterol and fatty acid synthesis were reduced. Taken together, these data establish that small-molecule S1P inhibitors are capable of reducing cholesterol and fatty acid synthesis in vivo and, therefore, represent a potential new class of therapeutic agents for dyslipidemia and for a variety of cardiometabolic risk factors associated with diabetes, obesity, and the metabolic syndrome.


Bioorganic & Medicinal Chemistry Letters | 2001

Small molecule somatostatin receptor subtype-2 antagonists.

Bruce A. Hay; Bridget Mccarthy Cole; Frank M. DiCapua; Glen W. Kirk; Marianne C. Murray; Rona A. Nardone; Dennis J. Pelletier; Anthony Paul Ricketts; Alan Robertson; Todd W. Siegel

The first potent small molecule sst2 antagonists are reported. Altering known sst2 agonist molecules yielded compounds with high sst2 binding affinity and full antagonist activity. Compound 7a, for example, displaced somatostatin binding to the sst2 receptor with an IC(50)=2.9 nM and antagonized somatostatin action with an IC(50)=29nM.


Tetrahedron Letters | 1994

Diastereoselective oxidation of substituted thietanes and stereoselective oxidation of their sulfoxides

Richard S. Glass; Waheguru Pal Singh; Bruce A. Hay

Abstract Oxidation of substituted thietanes 1a, b, and 6 with m-chloroperoxybenzoic acid preferentially gives the corresponding cis-sulfoxides with modest diastereoselectivity. Selective oxidation of the trans over the cis diastereomeric pairs of sulfoxides 2a, 3a; 2b, 3b; 7, 8 occurs with moderate selectivity with m-chloroperoxybenzoic acid. The basis for these selectivities is hydrogen bonding between the 3-substituent and the peracid.


Archive | 1990

Methods for making tetrahydroisoalpha and hexahydroisoalpha acids

Bruce A. Hay


Bioorganic & Medicinal Chemistry Letters | 2007

Aminopyrrolidineamide inhibitors of site-1 protease

Bruce A. Hay; Barbara Abrams; Allice Y. Zumbrunn; James J. Valentine; Laurie C. Warren; Stephen F. Petras; Lorraine D. Shelly; Angela Xia; Alison H. Varghese; Julie Hawkins; Jennifer A. Van Camp; Michael D. Robbins; Katherine T. Landschulz; H. James Harwood


Archive | 2001

Somatostatin antagonists and agonists that act at the SST subtype 2 receptor

Bruce A. Hay; Bridget Mccarthy Cole; Anthony Paul Ricketts


Archive | 2007

Pyrimidone Compounds As GSK-3 Inhibitors

Bruce Allen Lefker; Michael Aaron Brodney; Subas M. Sakya; Bruce A. Hay; Matthew D. Wessel; Edward L. Conn


Journal of Agricultural and Food Chemistry | 1991

Efficient one-step preparation of the beer additive tetrahydroiso-.alpha. acids

Bruce A. Hay; John W. Homiski


Archive | 1990

Steam stripping of odor forming impurities from hop flavors

Bruce A. Hay


Archive | 2001

Somatostatin antagonists and agonists

Bridget Mccarthy Cole; Anthony Paul Ricketts; Bruce A. Hay

Researchain Logo
Decentralizing Knowledge